Mary E. Klein
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
-
- Advanced Breast Cancer Therapies
Papers in
-
- Histone Deacetylase Inhibitors Research 2
- Ubiquitin and proteasome pathways 2
- Protein Degradation and Inhibitors 1
- Oncology 4
- Cancer-related Molecular Pathways 4
- Co-authors
- Andrew Koff (5 shared papers)William D. Tap (5 shared papers)Marta Kovatcheva (4 shared papers)Lara E. Davis (1 shared paper)Mark A. Dickson (3 shared papers)Samuel Singer (3 shared papers)Aimeé M. Crago (3 shared papers)Gary K. Schwartz (2 shared papers)
- Journals
- Cancer Cell (1 paper)Cancer Biology & Therapy (1 paper)The Journal of Perinatal & Neonatal Nursing (1 paper)Nature Communications (1 paper)Oncotarget (1 paper)
- Partner nations
- United States
In The Last Decade
Mary E. Klein
7 papers receiving 497 citations
Mary E. Klein's Hit Papers
Peers
Comparison fields: 5 of 57
- Oncology 295
- Pulmonary and Respiratory Medicine 275
- Genetics 84
- Cancer Research 56
- Aging 6
Countries citing papers authored by Mary E. Klein
This map shows the geographic impact of Mary E. Klein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E. Klein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E. Klein more than expected).
Fields of papers citing papers by Mary E. Klein
This network shows the impact of papers produced by Mary E. Klein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E. Klein. The network helps show where Mary E. Klein may publish in the future.
Co-authors
The 25 scholars most cited alongside Mary E. Klein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought Hit paper breakdown → | 2018 | 274 |
| 2 | 2015 | 102 | |
| 3 | 2017 | 62 | |
| 4 | 2018 | 35 | |
| 5 | 2013 | 20 | |
| 6 | 2017 | 5 | |
| 7 | 2011 | 1 | |
| 8 | 1988 | 0 |
About Mary E. Klein
Mary E. Klein is a scholar working on Molecular Biology, Oncology, Genetics, Pulmonary and Respiratory Medicine and Epidemiology, having authored 8 papers that have together received 499 indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (4 papers), Histone Deacetylase Inhibitors Research (2 papers), Advanced Breast Cancer Therapies (2 papers), Ubiquitin and proteasome pathways (2 papers), Microtubule and mitosis dynamics (1 paper), Protein Degradation and Inhibitors (1 paper), Myeloproliferative Neoplasms: Diagnosis and Treatment (1 paper) and Chronic Lymphocytic Leukemia Research (1 paper). The work is most often cited by research in Oncology (295 citations), Pulmonary and Respiratory Medicine (275 citations), Genetics (84 citations), Cancer Research (56 citations) and Aging (6 citations). Mary E. Klein has collaborated with scholars based in United States. Frequent co-authors include Andrew Koff, William D. Tap, Marta Kovatcheva, Lara E. Davis, Mark A. Dickson, Samuel Singer, Aimeé M. Crago, Gary K. Schwartz, Nicholas D. Socci and Rachael O’Connor. Their work appears in journals such as Cancer Cell, Cancer Biology & Therapy, The Journal of Perinatal & Neonatal Nursing, Nature Communications and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.